NCT03500380

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: UNKNOWN

Phase: PHASE2, PHASE3

Sponsor: RemeGen Co., Ltd.

Condition: Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

Signal summary

Public flags

Status signal: Unknown Status Signal

Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal

Results signal: Low Signal

Operational burden: large_enrollment_target_signal | rare_population_signal

Stopped reason

Context when available

No stop reason available in the current public record.